| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Polyrizon Ltd.$11.8
-1.39 (-10.54%)
Market Cap
27.20 M
EPS
-2.70
P/E Ratio
-
Value Trade
246.32 K
0.16 %
Week
19.65 %
1 Month
8.96 %
3 Month
323.12 %
6 Month
-99.38 %
5 Year
-99.38 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
76.86 K
52 Week Range
2.88 - 18.20
% held by Insiders
0.79 %
% held by Institutions
9.67 %
Enterprise Value
14.92 M
Total Shares
1.62 M
Short %
1.91 %
Float Shares
1.59 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PL-14 Allergy Blocker | allergic rhinitis | Preclinical | 2025-09-15 | |||
PL-14 Allergy Blocker | allergic rhinitis | Preclinical | 2025-09-15 | |||
PL-14 Allergy Blocker | allergic rhinitis | Preclinical | 2025-09-15 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PLRZ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Polyrizon Ltd. (PLRZ) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PLRZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLRZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLRZ
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLRZ Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PLRZ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PLRZPolyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
Polyrizon Ltd. has announced the publication of a U.S. patent application for its Trap & Target™ mucoadhesive polymer technology aimed at enhancing nasal drug delivery. This platform is designed to improve drug absorption and retention through the nasal mucosa, potentially benefiting various therapeutic applications. The technology combines biocompatible polymers to create effective formulations for both localized and systemic drug delivery.
Read more →PLRZPolyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
Polyrizon Ltd. has partnered with a prominent European medical center to conduct a human study on its NASARIX™ allergy blocker. This study will assess the nasal residence time of the formulation, which is crucial for understanding its protective barrier function. The findings are expected to support the company's regulatory strategy, including submissions to the FDA.
Read more →PLRZPolyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Polyrizon Ltd. announced the publication of its European patent application for its innovative mucoadhesive polymer technology aimed at enhancing nasal drug delivery. This technology seeks to improve drug absorption and retention time in the nasal cavity, addressing key challenges in the field. The patent publication is a significant milestone for Polyrizon as it strengthens its intellectual property portfolio and supports future pharmaceutical collaborations.
Read more →PLRZPolyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Ltd. has announced the addition of two new U.S. clinical sites for its NASARIX™ trial, bringing the total to three. These sites are crucial for the planned multi-center study evaluating the safety and efficacy of the NASARIX™ Allergy Blocker for seasonal allergic rhinitis. The company is optimistic about efficient patient recruitment and timely trial execution.
Read more →PLRZPolyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Polyrizon Ltd. has signed a Clinical Trial Agreement with a U.S. clinical site, marking a significant step towards human clinical trials for its NASARIX™ Allergy Blocker. The study will assess the safety, tolerability, and efficacy of the nasal spray in patients suffering from seasonal allergic rhinitis. This multi-center trial is expected to adhere to international Good Clinical Practice standards.
Read more →PLRZPolyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
Polyrizon Ltd. has announced the submission of amended claims for its U.S. patent application, expanding the scope of its intranasal drug delivery platform. The new claims include drug delivery systems and methods aimed at improving medication effectiveness. This move is part of Polyrizon's strategy to enhance its global intellectual property portfolio and potentially improve treatment outcomes across various therapeutic areas.
Read more →PLRZPolyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
Polyrizon Ltd. has filed a divisional patent application in Europe for its Trap & Target (T&T) platform technology, which aims to enhance intranasal drug delivery. This innovative system is designed to improve the bioavailability of active pharmaceutical ingredients and address challenges in drug delivery. The filing reflects the company's commitment to intellectual property protection and advancing healthcare solutions.
Read more →PLRZPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
Polyrizon Ltd. has successfully closed a $3.5 million registered direct offering and private placement with a single institutional investor. The offering included Ordinary Shares and pre-funded warrants, with proceeds aimed at supporting general corporate purposes. The company anticipates having over 2 million Ordinary Shares outstanding following the offering.
Read more →PLRZPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
Polyrizon Ltd. has announced a $3.5 million registered direct offering and private placement with a single institutional investor. The transactions involve the sale of Ordinary Shares and pre-funded warrants, with expected proceeds to be used for corporate purposes. The offering is set to close around April 8, 2026, pending customary conditions.
Read more →PLRZPolyrizon Provides 2025 and Recent Highlights
Polyrizon Ltd. has reported significant advancements in its intranasal protective solutions, including successful FDA meetings and preclinical results. The company is preparing for potential human clinical trials and has established collaborations to support its clinical development. With a strong cash position and a debt-free balance sheet, Polyrizon is well-positioned for future growth.
Read more →PLRZPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Polyrizon Ltd. has filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2025, with the SEC. The report details the company's progress in developing intranasal protective solutions, including their proprietary hydrogel technology. Shareholders can request copies of the report free of charge.
Read more →PLRZPolyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
Polyrizon Ltd. has signed a non-binding Memorandum of Understanding to acquire up to a 20% stake in Colugo Systems Ltd., a developer of advanced eVTOL drones. The deal, valued at up to $6 million, aims to enhance Polyrizon's capabilities in urban air mobility and defense sectors. The acquisition is expected to close within seven days after certain conditions are met.
Read more →PLRZPolyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
Polyrizon Ltd. has signed an agreement with a leading global preclinical CRO to advance its clinical development program. This partnership will facilitate comprehensive biocompatibility studies essential for regulatory submissions. The studies are expected to start in Q2 2026, supporting Polyrizon's timeline to initiate clinical trials later this year. The company has also achieved GMP production of clinical trial material and positive preclinical results.
Read more →PLRZPolyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study Raanana, Israel
Polyrizon Ltd. has announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material for its lead product candidate. This milestone is part of a previously established agreement with Eurofins CDMO AmatsiAquitaine S.A.S, aimed at aiding the supply chain for clinical trials. The GMP batch will support an upcoming clinical study in the U.S., furthering Polyrizon's commitment to developing intranasal solutions for respiratory protection against allergens and viruses. The company has shown consistency and stability in prior development batches, reinforcing the robustness of its manufacturing process.
Read more →PLRZPolyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Polyrizon Ltd. announced positive results from a study comparing its naloxone formulation to a commercial product. Conducted at the University of Parma, the study highlighted significantly better nasal deposition with Polyrizon's formulation. This success supports the company's Trap & Target technology and its broader intranasal platform strategy.
Read more →PLRZPolyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
Polyrizon Ltd. has signed a non-binding MOU to acquire a 51% stake in Arrow Aviation, a profitable private jet operator. The deal involves a cash investment of approximately $5.8 million and aims to leverage Arrow's established operations in the high-growth private aviation market. The acquisition is expected to enhance shareholder value and diversify Polyrizon's business focus.
Read more →PLRZPolyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
Polyrizon has entered a development agreement with Clearmind Medicine to create an intranasal formulation of MEAI, a non-hallucinogenic neuroplastogen. This collaboration aims to enhance the clinical development of MEAI for addiction-related and CNS conditions. Polyrizon's advanced intranasal delivery technology is expected to provide targeted and efficient drug administration.
Read more →PLRZPolyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
Polyrizon Ltd. has signed a non-binding MOU to acquire a 51% stake in Arrow Aviation, a private aviation company with significant revenue. This strategic move aims to diversify Polyrizon's operations into the growing private aviation sector, which is expected to reach $41.38 billion by 2030. The acquisition involves a cash investment of approximately $5.8 million and includes arrangements for debt forgiveness and future options for full ownership.
Read more →PLRZPolyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
Polyrizon Ltd. has initiated a usability study for its intranasal allergy blocker, NASARIX™, in compliance with FDA guidelines. This study aims to confirm product usability and support a streamlined regulatory path. Successful completion is expected to facilitate the start of clinical trials in Q3 2026, marking a significant step in the company's development strategy.
Read more →PLRZPolyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Polyrizon Ltd. has announced plans to explore revenue-generating investments in sectors such as defense, aviation, and AI while continuing to advance its intranasal medical pipeline. The company's Board of Directors has approved this initiative, leveraging its strong cash position and debt-free status to enhance financial stability and shareholder value. Products in development include allergy and viral blockers.
Read more →PLRZPolyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana,
Polyrizon Ltd. has successfully completed the branding process for its PL-14 allergy blocker, which will now be marketed as NASARIX. This significant milestone involves thorough trademark screening and aims to enhance the company's commercial readiness in the allergy market. NASARIX utilizes Polyrizon's unique Capture and Contain hydrogel technology, creating a protective barrier against allergens and viruses. The company anticipates introducing the product in line with its clinical and regulatory advancements.
Read more →PLRZPolyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
Polyrizon Ltd. announced positive results from a pre-clinical study of its PL-14 Allergy Blocker, which showed significant allergen-blocking performance compared to the standard comparator, HPMC. The study demonstrated that PL-14 effectively reduced the transfer of a major allergen, Der p 1, at all evaluated time points. The company plans to advance PL-14 towards clinical studies for allergy prevention.
Read more →PLRZAs Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
Polyrizon's PL-16 nasal spray emerges as a promising solution amid rising flu cases in the U.S. The product, based on a hydrogel technology, aims to create a barrier against respiratory viruses. With vaccination rates declining, PL-16 could serve as an additional layer of protection, especially during peak flu seasons. The company has submitted a Pre-Request for Designation to the FDA for potential over-the-counter status.
Read more →PLRZPolyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Polyrizon Ltd. announced plans to explore revenue-generating investments while continuing to advance its core medical device pipeline. The company is focused on developing intranasal protective solutions and has a strong cash position with no debt. This strategic initiative aims to enhance shareholder value while maintaining focus on product development.
Read more →PLRZPolyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses The PL-16 Viral Blocker has shown over 90% success in protection of cells against
Polyrizon Ltd. has submitted a Pre-Request for Designation (Pre-RFD) to the FDA for its PL-16 Viral Blocker, an intranasal product designed to reduce exposure to respiratory viruses such as influenza and colds. The PL-16 solution has demonstrated over 90% efficacy in protecting cells from viruses by creating a physical barrier in the nasal mucosa. This submission is timely given the ongoing challenges posed by seasonal respiratory infections, with the CDC reporting millions of symptomatic illnesses. Polyrizon plans to engage with the FDA for further development steps based on the feedback received.
Read more →PLRZPolyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
Polyrizon Ltd. announced positive results from its preclinical evaluation of an intranasal naloxone hydrogel formulation. The study demonstrated improved mucoadhesion and rapid permeation kinetics, indicating that the formulation could effectively deliver naloxone in emergency situations. The findings highlight the potential of Polyrizon's technology to enhance treatment reliability amid the escalating opioid crisis.
Read more →PLRZPolyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
Polyrizon Ltd. has completed a pre-submission meeting with the FDA for its PL-14 Allergy Blocker nasal spray. The meeting covered the product's development plan, manufacturing processes, and clinical strategy. This milestone is expected to facilitate regulatory alignment and support future clinical trials planned for 2026. The company aims to address the growing demand for allergy relief solutions.
Read more →PLRZPolyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversa
Polyrizon Ltd. has announced promising preclinical results for its intranasal naloxone hydrogel, demonstrating superior mucoadhesion compared to a marketed intranasal naloxone product. This study indicates that the hydrogel adheres to nasal tissue longer, potentially leading to more reliable opioid overdose reversal in emergencies. The findings underscore the advancements in Polyrizon's T&T hydrogel platform, reinforcing its potential in the intranasal drug delivery market. The results build on previously reported stability outcomes, showcasing the formulation's robustness under various conditions.
Read more →PLRZPolyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
Polyrizon Ltd. has successfully completed a significant manufacturing upscaling milestone for its nasal spray platform, PL-14. This advancement enables the transition from small-batch production to larger-scale manufacturing, ensuring high-quality standards. The company is now poised to support upcoming clinical trials expected to begin in 2026, aiming to address unmet needs in the nasal spray market.
Read more →PLRZPolyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
Polyrizon Ltd. announced positive in-vitro results for its PL-16 Viral Blocker, demonstrating broad-spectrum viral blocking efficacy against respiratory viruses like H1N1. The formulation acts as a reversible physical barrier, preventing viral entry without inactivating the virus. The results highlight the safety and effectiveness of the product, paving the way for future clinical studies.
Read more →PLRZPolyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd. announced positive results from a pre-clinical study of its PL-14 Allergy Blocker formulation, which effectively limits allergen penetration. The study demonstrated that PL-14 can form a protective barrier against the Der p 1 allergen, even under high exposure conditions. The company plans to advance clinical studies to further evaluate PL-14's efficacy.
Read more →PLRZPolyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Polyrizon Ltd. has submitted a comprehensive pre-submission package to the FDA for its PL-14 Allergy Blocker, aimed at providing relief from nasal allergies. This submission includes detailed documentation on manufacturing and clinical strategies, marking a significant step in the company's regulatory journey. The product is designed to create a barrier against allergens, potentially transforming treatment for millions suffering from allergic rhinitis.
Read more →PLRZPOLYRIZON LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Balance Sheets F-2 Condensed Statements of Comprehensive Loss F-3 Condensed Statement of Changes
Polyrizon Ltd. has released its unaudited condensed financial statements for the period ending June 30, 2025, highlighting significant changes in assets and equity. The company's cash and cash equivalents increased dramatically to $15,828, while it also reported an accumulated deficit of $5,243. Despite an operating loss of $2,485, management remains optimistic about sustaining operations for at least the next year. The report underscores the firm's ongoing struggle to secure consistent funding for its research and development activities.
Read more →PLRZPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd. announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating effective targeted deposition in the nasal vestibule. Conducted with the University of Parma, the study supports PL-14's potential as a barrier-forming treatment for allergic rhinitis. The company plans to advance preclinical validation towards clinical trials, highlighting the product's promising market potential.
Read more →PLRZPolyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon Ltd. has confirmed its compliance with Nasdaq listing requirements, as per a letter from the Hearings Advisor dated August 13, 2025. The company met the minimum bid price requirement and satisfied conditions set by the Nasdaq Hearings Panel. As a result, Polyrizon will continue to trade under the ticker symbol PLRZ.
Read more →PLRZPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study Ra'anana, Israel
Polyrizon Ltd. reported promising preclinical results for its PL-14 Allergy Blocker, showing effective targeted delivery to the nasal vestibule, a critical site for allergen contact. The study, conducted with the University of Parma, indicates PL-14 may serve as a barrier-forming treatment for allergic rhinitis. The formulation achieved over 60% deposition in this area and is positioned as a potential frontline preventive treatment. The company plans to advance the development of this product toward clinical trials, capitalizing on a growing market for allergy relief solutions.
Read more →PLRZPolyrizon Retains Nasdaq Listing Following Hearings Panel
Polyrizon Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market. This decision follows the company's commitment to address previous concerns regarding its capital-raising strategies. With a current cash balance of $15.68 million, Polyrizon aims to enhance shareholder value and ensure compliance with Nasdaq standards.
Read more →PLRZPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Polyrizon Ltd. announced positive preclinical results for its hydrogel-based Trap & Target platform, demonstrating effective intranasal delivery for CNS therapeutics. The study, conducted with the University of Parma, showed over 60% targeted deposition in key nasal regions, indicating potential for rapid brain access in emergencies. The company plans further validation and safety studies.
Read more →PLRZPolyrizon Announces Receipt of Nasdaq Delisting Notice
Polyrizon Ltd. has received a delisting notice from Nasdaq due to concerns over substantial shareholder dilution from a recent securities issuance. The company plans to appeal this decision by requesting a hearing, which will temporarily halt any delisting actions. This situation highlights the financial challenges faced by the development-stage biotech firm.
Read more →PLRZPolyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Polyrizon Ltd. announced promising results from ex vivo studies of its nasal protection platform, showcasing strong mucoadhesion and extensive nasal surface coverage. Conducted in collaboration with Prof. Fabio Sonvico's laboratory, the studies utilized rabbit nasal mucosa to evaluate the formulation's effectiveness. The findings suggest significant potential for therapeutic applications in intranasal drug delivery.
Read more →PLRZPolyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Polyrizon Ltd. has launched preclinical studies for its intranasal Benzodiazepine treatment aimed at improving emergency response for acute repetitive seizures. This initiative targets the growing epilepsy market, estimated at $3.15 billion. The studies will be conducted in collaboration with Professor Fabio Sonvico from the University of Parma. The company's proprietary Trap and Target™ platform aims to provide a more efficient and user-friendly method for administering seizure rescue medication.
Read more →PLRZPolyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model Raanana, Israel
Polyrizon Ltd. has reported positive results from a preliminary safety study of its PL-14 Allergy Blocker formulation, which was tested on human nasal tissue. The study indicated strong local tolerability, fulfilling a key milestone in the product's development. These findings are expected to support Polyrizon's clinical development plans, including upcoming FDA pre-submission meetings and anticipated clinical trials in the U.S. and Europe set to begin in late 2025 or early 2026. The company aims to offer a non-drug nasal spray that forms a physical barrier against airborne allergens.
Read more →PLRZAMENDED ARTICLES THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY ARTICLES OF ASSOCIATION OF Polyrizon Ltd . Preliminary 1. Definitions; Interpretation . (a) In these Articles, the following terms (whether or not capi
Polyrizon Ltd has amended its Articles of Association in accordance with the Companies Law of 1999. The amendments clarify definitions, share capital structure, and the company's ability to donate and modify share rights. These changes are typical in the governance of limited liability companies to ensure compliance and reflect current corporate needs.
Read more →PLRZPolyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements Raanana, Israel
Polyrizon Ltd. received notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price has been below $1.00 for the last 30 days. The company has been granted a 180-day period until October 6, 2025, to regain compliance. During this period, its shares will remain listed on the Nasdaq. If compliance is not achieved, the company could face delisting but may be eligible for an additional compliance period.
Read more →PLRZPolyrizon Engages Leading Branding Firm for Strategic Brand Development Raanana, Israel
Polyrizon Ltd. (Nasdaq: PLRZ) has engaged a prominent branding and trademark consultancy to develop a new brand identity for its Capture and Contain (C&C) hydrogel technology, aimed at providing a barrier against allergens and viruses. This strategic collaboration is viewed as a critical step toward the commercialization of the technology. The branding process will include extensive trademark assessments and compliance checks in the U.S. and European markets, aligning with Polyrizon's clinical and regulatory milestones. The C&C hydrogel represents a significant innovation in intranasal delivery systems.
Read more →PLRZPolyrizon Ltd. Announces Closing of $17.0 Million Private Placement
Polyrizon Ltd. has successfully closed a private placement totaling approximately $17.0 million, selling 35,416,667 Ordinary Units. The offering price for each unit was set at $0.48, which includes Ordinary Shares and Series A Warrants. The proceeds are intended for general corporate purposes and working capital needs. The Series A Warrants can be exercised after shareholder approval and have a term of 30 months. This marks a significant funding achievement for Polyrizon as it continues to refine its innovative intranasal hydrogel technology.
Read more →PLRZPolyrizon Ltd. Announces $17.0 Million Private Placement RAANANA, ISRAEL
Polyrizon Ltd. has announced a private placement that will generate approximately $17.0 million through the sale of Ordinary Units to institutional investors. The company will utilize these funds primarily for general corporate purposes and working capital. Each unit consists of one Ordinary Share and one Series A Warrant for the purchase of another Ordinary Share. The closing of the transaction is expected around April 1, 2025, pending customary closing conditions.
Read more →PLRZPolyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path for
Polyrizon Ltd. has announced the structuring of its clinical strategy for PL-14, an intranasal allergy blocker, as it prepares for a pre-submission meeting with the FDA. This strategy is designed to assess the drug's efficacy, safety, user experience, and nasal residence time. Following preclinical efforts, clinical trials are anticipated to start in the U.S. and Europe in late 2025 to early 2026. The company aims to provide significant value to individuals suffering from allergic rhinitis.
Read more →PLRZPolyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment Raanana, Israel
Polyrizon Ltd. has announced the initiation of preclinical studies for intranasal benzodiazepines, aimed at improving treatment options for acute repetitive seizures and status epilepticus. This development utilizes their proprietary drug delivery platform and is in collaboration with Professor Fabio Sonvico from the University of Parma. The studies focus on enhancing the efficiency of intranasal delivery, which offers notable advantages in emergency settings for epilepsy patients. The success of this research could contribute significantly to the growing market for epilepsy treatments.
Read more →PLRZPolyrizon Signs Non- Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments Raanana, Israel
Polyrizon Ltd. has signed a non-binding Letter of Intent to collaborate with a biotech firm focused on psychedelic therapies. This partnership aims to develop a novel intranasal formulation to improve the delivery and efficacy of psychedelic-based treatments. If successful, the project may lead to further clinical development and commercialization, with Polyrizon receiving royalty payments for future products. The agreement highlights the potential advantages of intranasal drug delivery and the opportunities within psychedelic medicine.
Read more →PLRZNOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the " Meeting ") of Polyrizon Ltd. (the " Company ") will be held on Thursday
Polyrizon Ltd. has announced its Annual General Meeting of Shareholders scheduled for April 17, 2025. The meeting will take place at the company's offices in Raanana, Israel, and provide an opportunity for shareholders to discuss the consolidated financial results for the year ended December 31, 2024. Shareholders are urged to participate either in person or via proxy to ensure their votes are represented. The Board recommends supporting the proposals outlined for the meeting.
Read more →PLRZPolyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Polyrizon Ltd. has initiated preclinical studies for an innovative intranasal Naloxone treatment aimed at combating opioid overdose. Conducted in collaboration with Professor Fabio Sonvico from the University of Parma, these studies will evaluate key parameters of Polyrizon's Trap and Target platform. The platform aims to improve Naloxone's bioavailability and delivery, potentially making it a more effective option during emergency overdose situations. The international opioid crisis necessitates advancements in Naloxone administration, which this initiative intends to address.
Read more →PLRZPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Polyrizon Ltd. has filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2024, with the SEC. The report details the company's innovative approach to developing intranasal hydrogels intended to serve as a barrier against viruses and allergens. Shareholders are encouraged to obtain copies of the report free of charge. Polyrizon continues to develop its technologies for enhanced drug delivery, though no specific challenges or risks were highlighted in the announcement.
Read more →PLRZPolyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform Raanana, Israel
Polyrizon Ltd. has announced the initiation of preclinical studies for an intranasal formulation of Naloxone, aiming to enhance opioid overdose treatment via its innovative Trap and Target (T&T) platform. This collaboration includes expert Professor Fabio Sonvico from the University of Parma. The studies will focus on vital parameters such as drug loading capacity and release kinetics. With the ongoing opioid crisis, Polyrizon's approach is designed to improve Naloxone's effectiveness and accessibility, catering to both emergency responders and individuals at risk.
Read more →PLRZPolyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target (T&T) Intranasal Drug Delivery Platform Raanana, Israel
Polyrizon Ltd. has filed a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) intranasal drug delivery platform. This application aims to protect the company's innovative system designed to enhance drug effectiveness by improving residence time in the nasal cavity. The T&T platform is significant for its potential to improve bioavailability of active pharmaceutical ingredients for various therapeutic applications. This filing represents a key step in strengthening Polyrizon's intellectual property portfolio as it strives to address healthcare challenges.
Read more →PLRZPolyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in f
Polyrizon Ltd. has started the preliminary Good Manufacturing Practice (GMP) process for its PL-14 allergy blocker, preparing for a planned clinical trial in 2025. The company is partnering with Eurofins CDMO to ensure compliance and high-quality production. PL-14 aims to tackle allergy-related health challenges with its intranasal treatment, which is part of the growing nasal spray market projected to exceed $23 billion by 2029. Polyrizon emphasizes its commitment to achieving quality standards in the development of this innovative solution.
Read more →PLRZPolyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies Raanana, Israel
Polyrizon Ltd. announced the publication of a U.S. national patent application for its innovative hydrogel nasal technologies on December 30, 2024. This application covers core technologies aimed at blocking nasal threats and optimizing drug delivery. Their Capture and Contain platform provides a protective barrier against biological threats, while the Trap and Target platform enhances effective medication delivery. As a development-stage biotech firm, uncertainties and risks may affect future outcomes and performance.
Read more →PLRZPolyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs Raanana, Israel
Polyrizon Ltd. has appointed Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs. This decision aligns with the company's preparations for its clinical trial of PL-14, expected to begin in 2025. Dr. Meir brings significant experience from her previous roles and is expected to provide strategic insights that will enhance Polyrizon's operational capabilities. The appointment indicates the company's commitment to high regulatory compliance and clinical standards.
Read more →PLRZPolyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
Polyrizon Ltd. has entered a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to supply Clinical Trial Material for its upcoming PL-14 clinical trial, expected to begin in 2025. This partnership ensures a reliable source for producing the allergy blocker. The trial will assess the safety and efficacy of PL-14 as an innovative allergy treatment, aligning with Polyrizon's mission to address allergy-related health issues through intranasal hydrogels.
Read more →PLRZPolyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance Raanana, Israel
Polyrizon has announced the appointment of Asaf Azulay as its new Vice President of Regulatory Affairs and Quality Assurance. This strategic move is intended to ensure the company adheres to the highest industry standards while advancing its innovative biotech developments. Azulay's extensive experience in the medical devices industry is expected to aid Polyrizon in navigating the intricate global regulatory landscape. The company emphasizes its mission to deliver safe, effective solutions to the market, particularly through its intranasal hydrogel technology.
Read more →PLRZPolyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial The engagement with an EU-based GMP manufacturing facility enables timely produ
Polyrizon has entered into a GMP manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to produce Clinical Trial Material (CTM) for its PL-14 allergy blocker. This initiative is part of Polyrizon's preparations for a clinical trial scheduled to commence in 2025, aimed at evaluating the product's safety and efficacy. The collaboration is expected to provide a reliable manufacturing source, aligned with regulatory standards in the USA and Europe, and signifies a major step forward for the company's allergy treatment efforts.
Read more →PLRZPolyrizon Announces Closing of $4.2 Million Initial Public Offering
Polyrizon Ltd. announced the successful closing of its initial public offering, raising $4.2 million by offering 958,903 units priced at $4.38 each. The offering included a 45-day option for Aegis Capital to purchase additional units, which could increase total proceeds to approximately $4.82 million. The company intends to use the funds for clinical development, research, debt repayment, and general corporate purposes. This funding is crucial for advancing their innovative hydrogels designed for nasal delivery applications.
Read more →PLRZPolyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker "PLRZ" Raanana, Israel
Polyrizon Ltd. announced the pricing of its initial public offering (IPO) at $4.2 million, with shares expected to trade on the Nasdaq Capital Market under the ticker 'PLRZ' starting October 30, 2024. The IPO includes 958,903 units priced at $4.38 each, with gross proceeds potentially reaching $4.82 million if an overallotment option is exercised. Proceeds are allocated for preclinical and clinical development, research, debt repayment, and general corporate purposes.
Read more →PLRZPolyrizon Filed a US Patent Application for Formulations and Methods for Preventing Viral Infections by COVID-19 Virus
OMER, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that following the signing of a binding letter of intent with Polyr
Read more →Competitive Position
How PLRZ ranks across every disease it competes inCompetitive Position is a premium feature
See how PLRZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial